Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus (Nasdaq: SLP) announced that it will release its third quarter fiscal 2024 financial results after market close on July 2, 2024. A conference call to discuss these results will be held at 5:00 p.m. EDT on the same day. The call is open to investment professionals and shareholders, who can join via webcast or by dialing in. The webcast will be available for replay on the Simulations Plus investor relations webpage about an hour after the call concludes.
- Financial results release scheduled for July 2, 2024, indicating timely disclosure.
- Conference call with management to provide in-depth analysis and discussion of Q3 results.
- Replay of the webcast available for those unable to join live, increasing accessibility.
- No preliminary financial figures or guidance provided ahead of the earnings release.
- Potential for negative market reaction if results do not meet investor expectations post-market close.
Conference call to be on Tuesday, July 2, 2024, at 5 p.m. EDT
Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on the investor relations page of the Simulations Plus website at www.simulations-plus.com/investorscorporate-profile/corporate-profile/ where it will also be available for replay approximately one hour following the call.
About Simulations Plus
With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the Biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618346263/en/
Simulations Plus Investor Relations
Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com
Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com
Source: Simulations Plus, Inc.
FAQ
When will Simulations Plus release its Q3 fiscal 2024 earnings?
What time is the Simulations Plus Q3 fiscal 2024 earnings conference call?
How can I join the Simulations Plus Q3 fiscal 2024 earnings conference call?
Will there be a replay available for the Simulations Plus Q3 fiscal 2024 earnings call?
